[Efficacy and safety of the use of alirocumab in real clinical practice].
Terapevticheskii arkhiv(2023)
摘要
The inclusion of alirocumab in the treatment regimen contributed to the stable course of atherosclerosis-associated diseases, the achievement of LDL cholesterol targets in 77.8% of patients, was not accompanied by side effects during 2.5 years therapy.
更多查看译文
关键词
alirocumab,efficacy,clinical practice
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要